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Abstract
Background—Recent outbreaks of swine-origin influenza A(H3N2) variant (H3N2v) viruses 
have raised public health concerns. Previous studies indicated that older children and young adults 
had the highest levels of hemagglutination-inhibition (HI) antibodies to 2010–2011 H3N2v 
viruses. However, newly emerging 2013 H3N2v have acquired antigenic mutations in the 
hemagglutinin at amino acid position 145 (N145K/R). We estimated the levels of serologic cross-
reactivity among humans primed with seasonal influenza A(H3N2) (sH3N2), using postinfection 
ferret antisera. We also explored age-related HI antibody responses to 2012–2013 H3N2v viruses.
Methods—Human and ferret antisera were tested in HI assays against 1 representative 2012 
H3N2v (145N) and 2 2013 H3N2v (145K/R) viruses, together with 9 sH3N2 viruses circulating 
since 1968.
Results—Low levels of cross-reactivity between the H3N2v and sH3N2 viruses from the 1970s–
1990s were observed using postinfection ferret antisera. The overall seroprevalence among the 
sH3N2-primed population against 2012–2013 H3N2v viruses was >50%, and age-related 
seroprevalence was observed. Seroprevalence was significantly higher to 2013 H3N2v than to 
2012 H3N2v viruses among some children likely to have been primed with A/Sydney/5/97-like 
(145K) or A/Wuhan/359/95-like viruses (145K).
Conclusions—A single substitution (N145K/R) was sufficient to affect seropositivity to H3N2v 
viruses in some individuals. Insight into age-related antibody responses to newly emerging H3N2v 
viruses is critical for risk assessment and pandemic preparedness.
Correspondence: X. Lu, MD, 1600 Clifton Rd NE, Mailstop G-16, Atlanta, GA 30333 xal0@cdc.gov.
aF. L. and V. V. contributed equally to this work.
Presented in part: “Options IX for the Control of Influenza,” Chicago, Illinois, 24–28 August 2016.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments 
should be addressed to the corresponding author.
Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.
Supplement sponsorship. This work is part of a supplement sponsored by the Centers for Disease Control and Prevention.
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
HHS Public Access
Author manuscript
J Infect Dis. Author manuscript; available in PMC 2018 September 15.
Published in final edited form as:
J Infect Dis. 2017 September 15; 216(Suppl 4): S539–S547. doi:10.1093/infdis/jix093.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Seroprevalence study; human seasonal Influenza A(H3N2) viruses; swine-origin Influenza 
A(H3N2) variant viruses; antigenic analysis; serum HI antibody response
Triple-reassortant swine influenza A(H3N2) viruses (tr-H3N2 SIVs), which contain genes 
from human, classic swine, and avian influenza A viruses, have been enzootic among swine 
herds in the United States since 1998 [1, 2]. The genes encoding the principal surface 
glycoprotein of the tr-H3N2 SIVs, hemagglutinin (HA), are genetically similar to the 1995, 
1997, or 2010–2011 human seasonal influenza A(H3N2) viruses (sH3N2) [1–3]. The first 
human case in the United States was identified in 2009 [4], and 2009–2010, 7 additional tr-
H3N2–infected cases were reported in the United States, primarily among children [5].
In 2010, a novel reassortant H3N2 SIV containing 7 genes from the tr-H3N2 and the matrix 
gene from influenza A(H1N1)pdm09 virus was identified in US pigs [6, 7]. From August 
2011 to October 2016, a total of 364 human infections with the novel reassortant H3N2 
variant (H3N2v) viruses were reported from 13 states [8, 9] (http://www.cdc.gov/flu/
swineflu). Twenty-one patients were hospitalized, and 1 fatal case was identified. The 
number of H3N2v-infected cases was probably underestimated, and limited person-to-
person transmission was likely [10]. However, no sustained or community transmission of 
this virus had been identified [10]. The majority of patients with H3N2v virus were children 
aged <12 years and had reported swine exposure at agricultural fairs [8, 9].
Antibodies against HA are a primary determinant of protection to influenza infection [11]. 
Serum hemagglutination-inhibition (HI) antibodies that bind or block the receptor-binding 
site of HA are widely accepted immune correlates of protection [12]. An HI titer of 40 is 
generally considered a 50% protective titer for sH3N2 viruses in adult populations [12]. 
Previous seroprevalence studies conducted by 6 countries indicated that approximately 
25%–50% of the human populations were seropositive (with HI titers ≥40) to 2010–2011 
H3N2v viruses [13–18]. Age-related seroprevalence, based on the percentage of HI titers 
≥40, was noted. The older children and young adults had the highest levels of seropositivity 
to H3N2v viruses, but most young children (aged <10 years) and older adults (aged 40–60 
years) had few or no cross-reactive HI antibodies to these viruses. The reasons for this 
apparent age-related seroprevalence were not discussed in detail [13–18]. Immunization with 
the 2010–2011 or 2011–2012 trivalent inactivated seasonal influenza vaccine did not result 
in HI antibody response to H3N2v viruses in children aged <3 years [19], but it slightly 
boosted the levels of cross-reactive HI antibodies among some older children, adults, and the 
elderly [15, 19]. On the other hand, vaccination with inactivated A/Beijing/32/1992 vaccine 
or 2011–2012 trivalent inactivated seasonal influenza vaccine failed to induce HI antibody 
response to 2011 H3N2v virus and did not provide any significant cross-protection against 
the H3N2v virus infection in ferrets [20].
The sH3N2 HA genes introduced into the US SIV gene pool in the 1990s followed an 
evolutionary path in the swine population separate from their human counterparts [5, 21]. 
This resulted in 2009–2012 H3N2 SIVs, including H3N2v virus, being antigenically distinct 
from 1990s tr-H3N2 SIVs and sH3N2 viruses circulating since 1979, observed with HI tests 
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using postinfection ferret antisera [15, 22]. Contemporary H3N2 SIVs demonstrated 
substantial antigenic diversity [21], and continuous genetic and antigenic evolutions of 
H3N2 SIVs could generate new SIVs with greater antigenic distance from historical and 
contemporary sH3N2 viruses. Of particular note are the 2013 H3N2v strains, which possess 
substitutions at position HA-145 (N145K/R). These H3N2v viruses caused 18 human 
infections in 2013, mainly among children ≤10 years old (http://www.cdc.gov/flu/swineflu).
Amino acid position 145, located in antigenic site A of H3 HA near the tip of the globular 
head and the receptor-binding site [23], has been under continual antibody-driven selection 
since the 1968 H3N2 pandemic [24, 25]. The amino acid substitutions at residue 145 of 
sH3N2 viruses (S145N, N145K, K145N, and N145S) have been identified in multiple 
antigenic drift events in the past [26–29]. A single N145K substitution was shown to have a 
large antigenic effect responsible for the A/Sichuan/1987 to A/Beijing/1989 and A/Beijing/
1992 to A/ Wuhan/1995 cluster transitions detected by ferret antisera [26, 27]. Convalescent 
serum samples collected in 1991 from children (aged 12–14 years) infected with sH3N2 
viruses containing 145K either lost or reduced their binding capacity to a mutant virus as 
well as to the 1993–1994 field strains containing 145N [30]. Moreover, the S145N/R or 
N145K substitution was associated with an emergence of a new antigenic cluster or outliers 
in European and the US pigs [21, 31].
The human infections with H3N2v viruses possessing the HA N145K/R mutations in 2013 
are of public health concern. In the current study, we evaluated the levels of HI antibodies to 
1 2012 H3N2v (145N) virus, 2 2013 H3N2v (145K/R) viruses, and 9 1968–2007 sH3N2 
viruses in a large set of human serum samples (from subjects aged 6 to ≥80 years) and 
postinfection ferret antisera. We also explored whether previous exposures to different 
sH3N2 antigenic variants is associated with age-related cross-reactivity in US children. 
Analysis of the antigenic relationships among H3N2v and sH3N2 viruses and continuous 
monitoring of age-based seroprevalence to newly emerging H3N2v drift strains are 
important for risk assessment and development of medical countermeasures.
MATERIAL AND METHODS
Viruses
Influenza viruses were propagated either in the allantoic cavity of 10-day-old embryonated 
eggs or in Madin-Darby Canine Kidney cells, following procedures published elsewhere 
[32] under BSL2-enhanced conditions for H3N2v or BSL2 conditions for sH3N2 viruses.
Serum Samples
Human serum samples collected in 2010 (N = 1007; subjects aged 6 to ≥80 years) were 
randomly selected from a large set of serum samples provided by the National Health and 
Nutrition Examination Survey. The protocol for testing of these serum samples at the 
Centers for Disease Control and Prevention (CDC) was reviewed and approved by the 
Institutional Review Board of the CDC’s National Center for Immunization and Respiratory 
Diseases and the Research Ethics Review Board of CDC’s National Center for Health 
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Statistics. Postinfection ferret antisera were prepared by intranasal inoculation with a single 
dose of wild-type virus.
HI Assay
Serum samples were treated with receptor destroying enzyme (Denke-Seiken) to remove 
nonspecific inhibitors and adsorbed with packed turkey red blood cells to remove 
nonspecific agglutinins before testing with 4 HA units of virus and 0.5% turkey red blood 
cells by means of HI assays [33].
Statistical Analyses
Fisher exact tests and t tests were used to analyze seroprevalence and geometric mean titers 
(GMTs), respectively. Differences were considered significant at P < .05. SAS software 
(version 9.3; SAS Institute) was used for statistical analyses.
RESULTS
Antigenic Analysis
The antigenic relationship among 3 2012–2013 H3N2v and 9 sH3N2 viruses associated with 
the majority of severe epidemics since 1968 was determined by HI assays using primary-
infection ferret antisera. Three H3N2v viruses possessing 145N (A/Ohio/13/2012 [OH/
13/12]), 145K (A/Indiana/06/2013 [IN/6/13]), or 145R (A/Indiana/17/2013 [IN/17/13]) were 
tested with HI assays, together with sH3N2 viruses representative of 9 antigenic clusters 
since 1968. Nine sH3N2 viruses, their prevalent eras, prominent seasons, and vaccine-use 
eras in the United States are summarized in Table 1, based on previous publications [34, 35] 
and the annual US influenza surveillance data.
As shown in Table 2, the 3 H3N2v viruses were well inhibited by ferret antisera raised 
against these viruses, although somewhat reduced cross-reactivity (2–4 fold) was noticed 
between 2012 H3N2v (145N) and 2013 H3N2v (145K/R) viruses. However, these viruses 
were not inhibited or were poorly inhibited by antisera raised against all 9 sH3N2 viruses. 
The 3 antisera raised by H3N2v viruses also demonstrated low levels of cross-reactivity to 
the sH3N2 viruses from the1970s–1990s, and 2 antisera raised to WH/95 or BJ/92 showed 
low levels of cross-reactivity with the 2012 and/or 2013 H3N2v viruses. These data indicate 
that the 2012–2013 H3N2v viruses were antigenically distinct from the 1968–2007 sH3N2 
viruses but antigenically related to the sH3N2 viruses from the1970s–1990s.
Age-Related Seroprevalence
To determine the seroprevalence of HI antibodies to OH/13/12, IN/6/13, and IN/17/13, a 
large set of human serum samples (N = 1007) collected from consecutive ages (6 to ≥80 
years) in 2010 were examined in HI assays. Most samples yielded similar HI titers against 
IN/6/13 and IN/17/13 (data not shown). Therefore, seroprevalence, determined on the basis 
of an HI titer ≥40, and HI GMTs were evaluated for OH/13/12 and IN/6/13 across 9 separate 
age group categories (Table 3). We also evaluated seroprevalence and HI GMT differences 
between OH/13/12 (145N) and IN/6/13 (145K).
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The overall seroprevalence was similar against OH/13/12 (54%) and IN/6/13 (55%), 
although the 2 viruses showed distinctive age-related patterns. Low seropositive rates for 
both H3N2v viruses were observed among children 6–9 years old. The proportion of 
seropositivity increased with age, peaked among those aged 20–29 years, then dropped to 
approximately one-third among those aged 40–49 or 50–59 years, and remained between 
39% and 52% among those aged 60–69, 70–79, or ≥80 years. The GMTs had the same age-
related trend as the seroprevalence. However, significant differences (P < .01) in 
seroprevalence and HI GMTs between IN/6/13 and OH/13/12 were observed in those aged 
10–19 or 30–39 years (Table 3).
Interestingly, 8% of individuals (83 of 1007; median age, 17 years) showed the pattern of 
higher seroprevalence to IN/6/13 than to OH/13/12 (HI titers ≥40 to IN/6/13 and ≥4-fold 
higher for IN/6/13 than for OH/13/12). In contrast, 4% (38 of 1007; median age. 47 years) 
showed the pattern of higher seroprevalence to OH/13/12 than to IN/6/13 (HI titers ≥40 to 
OH/13/12 and ≥4-fold higher for OH/13/12 than for IN/6/13). These 2 patterns were also 
age related: 61% with higher seroprevalence to IN/6/13 were aged 8–20 years, and 95% with 
higher seroprevalence to OH/13/12 were aged ≥21 years.
Likely Association Between Seroprevalence in Older Children and First Exposure to sH3N2 
Viruses in the 1990s
To determine whether the HI antibodies cross-reactive to 2012–2013 H3N2v viruses were 
associated with exposures to historic sH3N2 viruses, all serum samples from children (n = 
211; aged 6–18 years) from a set of 1007 samples were tested against 2 H3N2v and 8 
sH3N2 viruses. These serum samples showed unmeasurable HI antibody response (titer, 
<10) against AI/68, VIC/75, and BK/79 (data not shown). The age distributions for HI 
antibodies to the 2 H3N2v and 5 1987–2007 sH3N2 viruses are presented in Figure 1.
The majority of children (79%) aged 6–9 years (born 2001–2004) showed seropositivity to 
BR/07, but ≤17% showed seropositivity to the 2 H3N2v viruses. Increased seroprevalence to 
IN/6/13 (46%) and OH/13/12 (36%) were observed among 10–11-year-olds (born 1999–
2000), along with increasing seroprevalence (86%) to SY/97, which circulated between 1997 
and 2000. Further increased seroprevalence to IN/6/13 (80%) was observed in the 12–13- 
and 14–15-year age groups (born 1995–1998), accompanied by increased seroprevalence 
(77%) to WH/95, which circulated between 1995 and 1998. Among 16–18-year-olds (born 
1992–1994), seroprevalence (~90%) to IN/6/13 and OH/13/12 was the highest, with 
increasing seroprevalence (88%) to BJ/92, which circulated between 1992 and 1996. 
Analysis using GMTs demonstrated the same age-related trend as seroprevalence. These 
data suggested that HI antibodies cross-reactive to 2012 and/or 2013 H3N2v viruses among 
children (aged 10–18 years) were probably associated with their first exposure to different 
sH3N2 viruses in the 1990s.
To further clarify the age-related seroprevalence in the older children, the HI data from 141 
children (aged 12–18 years) were selected and further analyzed, and 124 children (88%) 
were seropositive to either IN/6/13 or OH/13/12, or both. Finally, we selected the 118 
H3N2v-seropositive children and grouped them into 3 groups based on the 3 unique HI 
antibody patterns against the 4 1987–1997 sH3N2 viruses (Figure 2 and Supplementary 
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Tables 1–3). Group 1 (median age, 13 years in 2010) included children showing the highest 
HI titers to SY/97, which were significantly higher (≥4-fold) than titers to WH/95, BJ/92, 
and SH/87 (Figure 2A and Supplementary Table 1). Group 2 (median age, 15 years in 2010) 
included children exhibiting similar levels (within 2-fold) of HI antibody titers against 
SY/97 and WH/95, with titers to WH/95 virus significantly higher than those to BJ/92 and 
SH/87 (Figure 2B and Supplementary Table 2). Group 3 (median age, 17 years in 2010) 
included children with similar levels of HI titers to SY/97, WH/95, and BJ/92, with titers to 
BJ/92 significantly higher than those to SH/87 (Figure 2C and Supplementary Table 3).
Consistent with recent publications [36–38], our data also showed varied levels of cross-
reactive HI antibodies to SH/87, which circulated before the birth of these children (Table 1 
and Supplementary Tables 1–3). Considering that the first sH3N2 virus infection can occur 
among children aged 2 months to 7 years old [39, 40], the age distribution (Figure 3) 
correlated well with what is known as the “period of prevalence” of the SY/97, WH/95, and 
BJ/92 antigenic clusters (Supplementary Table 4). Thus, it is reasonable to suggest that most 
children, if not all, in groups 1, 2, and 3 were highly likely to be primed with the SY/97, 
WH/95, and BJ/92 clusters, respectively. It is noteworthy that 6 H3N2v-seropositive children 
were excluded from the analysis (data not shown), including 1 child with the highest HI 
titers to sH3N2 viruses circulated after 2000, 1 with low HI titers to the sH3N2 viruses 
tested, and 4 with HI titers to WH/95 2-fold higher than those to BJ/92 but titers to IN/6/13 
≥4-fold higher than those to OH/13/12. The antibody population of these 4 serum samples 
was verified by antibody adsorption assays; WH/95-specific antibody, but not BJ/92-specific 
antibody, was detected, suggesting that these children were probably primed with WH/95-
like viruses (data not shown). Overall, the 118 samples analyzed in Figure 2 represented 
95% of H3N2v-seropositive children available in this age group.
All children in group 1, likely to have been primed with SY/97-like virus, showed 
seropositivity to IN/6/13 and SY/97; 62% also showed seropositivity to OH/13/12 (Figure 
2D). Although only a small portion of the children (21%) showed significantly higher HI 
titers (≥4 fold) against IN/6/13 than against OH/13/12, the data suggested that a certain 
portion of antibodies in these children could recognize an epitope containing 145K on IN/
6/13 HA. All children in group 2, likely to have been primed with WH/95-like virus, showed 
seropositivity to IN/6/13, WH/95, and SY/97, but only 43% showed seropositivity to OH/
13/12 (Figure 2E). Most children (91%) in group 2 had significantly higher HI titers ((≥4 
fold) against IN/6/13 than against OH/13/12, thus suggesting that dominant HI antibodies 
cross-reacting with IN/6/13 in most WH/95-primed children bind to an epitope containing 
145K. Most children (98%) in group 3, likely to have been primed with BJ/92-like virus, 
showed seropositivity and similar levels of HI antibody responses to the 2 H3N2v and the 3 
sH3N2 viruses (Figure 2F). Taken together, these data suggested that primary infections with 
the SY/97, WH/95, or BJ/92 cluster were highly likely to be associated with the age-related 
seroprevalence to 2012–2013 H3N2v viruses in older children.
Comparison of Amino Acid Sequence in Antigenic Site A Among H3N2 Viruses
To better understand the molecular basis of the different seroprevalence patterns to OH/
13/12 and IN/6/13 in children, we compared HA1 amino acid sequences of the H3N2v and 
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the sH3N2 viruses. Because there was only a single amino acid difference at position 145 
(antigenic site A) in the entire HA1 domain between the OH/13/12 and IN/6/13, but the 2 
viruses demonstrated a moderate antigenic variation (2–4-fold HI titer differences; Table 2), 
our analysis focused on antigenic Cross-Reactive Antibody to H3N2v Viruses • JID 
2017:216 (Suppl 4) • S545 site A. An amino acid difference in antigenic site A between the 
sH3N2 and the H3N2v viruses is presented in Table 4. The IN/6/13 and WH/95 shared 
several amino acids in antigenic site A, particularly the 145K, which might provide an 
explanation of the high seroprevalence to IN/6/13 among possible WH/95-primed children 
[30]. The data also suggested that the majority of HI antibodies cross-reactive to IN/6/13 
among WH/95-primed children bound to an epitope possessing 145K. A single N145K 
substitution in H3N2v virus HA is sufficient to change an individual’s seropositivity and 
significantly influence seroprevalence in some age groups.
DISCUSSION
Using human and postinfection ferret antisera, we evaluated the levels of HI antibodies 
against 2012–2013 H3N2v viruses, together with 9 epidemiologically important sH3N2 
viruses circulating since 1968. Children born after 2000 had lowest level of cross-reactive HI 
antibodies to 2012–2013 H3N2v viruses tested. This is consistent with results of previous 
population serosurveys with 2010–2011 H3N2v viruses [13–18], suggesting that young 
children are at high risk of infection with the H3N2 SIVs. In agreement with the serological 
findings, the majority of confirmed H3N2v virus infections in 2011–2015 occurred in 
children ≤10 years old [9] (http://www.cdc.gov/flu/swineflu). However, more than half of 
individuals born before 2000 showed seropositivity to 2012–2013 H3N2v viruses.
Low degrees of serologic cross-reactivity between 1975–1997 sH3N2 and the 2012–2013 
H3N2v viruses were observed in ferrets after primary infection. However, a high degree of 
cross-reactivity was observed in some individuals after multiple exposures. Moreover, age-
related seroprevalence was observed in humans, and most older children and young adults 
showed seropositivity to the H3N2v viruses. A 2016 study indicated that HI antibody 
patterns in ferrets and young children after primary infection with sH3N2 viruses is 
generally similar [38]. An earlier study found that primary infection with sH3N2 virus could 
occur in 2-month-old infants, and the second infection in those 12 months old [40].
Our cross-HI data demonstrated that most individuals tested in this study had experienced 
secondary or even >2 exposures to sH3N2 viruses. Secondary exposures with antigenic 
drifted strains could shape HI antibody patterns by producing antibodies targeting different 
subdominant epitopes on the HA [41–43], which may be responsible for the difference 
observed between the ferrets and humans in this study. It would be interesting to study how 
the age-related HI antibodies change as an individual experiences first, second, or multiple 
exposures to sH3N2 antigenic variants. Consistent with previous findings [36, 37, 44], our 
data indicated that primary exposure with sH3N2 viruses influenced HI antibody response 
thereafter. Because HI antibodies target the HA globular head and neutralizing antibodies 
target both globular head and stalk domain [45], it would also be interesting to investigate to 
what extent such primary exposure with sH3N2 virus affects the neutralizing antibody 
response.
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A single substitution (N145K) was sufficient to affect individuals’ seropositivity to 2012–
2013 H3N2v viruses. Significantly higher seropositivity (80%) to IN/6/13 (145K) compared 
with OH/13/12 (145N; 44%) was observed in children born between 1995 and 1998. The 
seropositivity to IN/6/13 among older children was also remarkably higher than that to 2011 
H3N2v viruses possessing 145N [13, 14, 16]. BJ/92, WH/95, and SY/97 are the 
representative sH3N2 viruses circulated between 1992 and 2000. To better understand the 
age-related antibody patterns, we have, for the first time, determined the priming sH3N2 
virus in older children with unknown exposure histories. The priming sH3N2 viruses, 
determined based on each child’s HI antibody pattern, were consistent with surveillance data 
reflecting the period during which the 3 sH3N2 antigenic cluster circulated in the US 
population. Grouping the children into 3 sH3N2 primed groups allowed us to understand 
how sH3N2 priming histories influence cross-reactivity for 2012–2013 H3N2v viruses. For 
example, most children who were highly likely to have been primed with WH/95-like 
viruses showed similar levels of HI antibody responses to the WH/95, SY/97, and IN/6/13 
viruses, all 3 containing 145K, but their HI antibody levels against OH/13/12 (145N) and 
BJ/92 (145N) were significantly lower or even undetectable.
Previous studies showed that convalescent serum samples from children infected with BJ/89-
like viruses (145K) and antisera from ferrets infected with WH/95-like virus (145K) had 
significantly decreased HI activity to H3N2 viruses possessing 145N [30, 46]. The addition 
of glycans at Asn133 on SY/97 HA should not mask the 140 loop [47]. Moreover, a human 
145K-specific monoclonal antibody could cross-react with SY/97-like viruses [48]. The HI 
pattern in the WH/95-primed children, together with previous findings [30, 38, 46–48] 
suggests that reinfection with SY/97-like viruses probably occurred in these children. The B 
memory cells targeting an epitope possessing 145K might be restimulated by reinfection 
with SY/97-like viruses, which might resulted in dominance of the antibodies directed to the 
epitope possessing 145K in WH/95-primed children [41]. These antibodies are likely to 
recognize WH/95 (145K), SY/97 (145K), and IN/6/13 (145K) but not OH/13/12 (145N).
Children who were likely to have been primed with SY/97-like virus showed significantly 
higher levels of HI antibodies to SY/97, compared with 2012–2013 H3N2v viruses, 
indicating that the majority of these antibodies could not cross-react with 2012–2013 H3N2v 
viruses. Some SY/97-primed children showed the pattern of higher seroprevalence to IN/
6/13 than to OH/13/12, suggesting that some antibodies binding to an epitope possessing 
145K have, in part, contributed to the cross-reactivity to IN/6/13 virus. Children primed with 
BJ/92-like virus showed equally high levels of HI antibody activity to 2012–2013 H3N2v 
and 1992–1997 sH3N2 viruses, regardless of 145N or 145K, suggesting that there are 
alternate common epitope(s) between the sH3N2 and 2012–2013 H3N2v viruses. The 
pattern of higher HI antibody activity to OH/13/12 than to IN/6/13 was observed mainly in 
individuals born before 1989. It is unknown whether this pattern was associated with 
exposures to sH3N2 viruses possessing 145N, which circulated in 1970s and 1980s [26]. 
Further studies are warranted to clarify the influence of priming histories in the cross-
reactivity to H3N2v viruses among adults and elderly. The nature of age-related cross-
reactive antibodies in different age populations should also be further addressed.
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H3N2v viruses can efficiently replicate and transmit in mammals [49]. The continued 
evolution of H3N2 SIVs among pigs may generate a novel virus, to which the majority of 
humans, particularly older children and younger adults, may have little or no preexisting 
immunity. Improved surveillance in pigs for newly emerging H3N2 SIVs remains important. 
Insight into age-related cross-reactive antibody patterns against circulating SIVs among 
different age groups is critical in identifying the risks of viruses in causing human infection 
and interspecies transmission with these viruses, and their pandemic potentials.
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Figure 1. 
Prevalence of hemagglutination-inhibition (HI) antibodies cross-reactive to A(H3N2) variant 
(H3N2v) swine influenza viruses in US children is likely to be associated with exposures to 
1990s human seasonal influenza A(H3N2) (sH3N2) viruses. Serum samples from children 
aged 6 to 18 years (n = 211) were collected in 2010. Seroprevalence (A) and HI geometric 
mean titers (GMTs) (B) for 2 H3N2v viruses are depicted in bars for A/Indiana/06/2013 (IN/
6/13) and A/Ohio/13/2012 (OH/13/12). The seroprevalence and GMTs for the 5 human 
sH3N2 viruses isolated between 1987 and 2007 are shown as lines. Age groups at the time 
of serum sample collection (2010) and years of birth are shown on the x-axis. The 
seroprevalence and HI GMTs against IN/6/13 compared with OH/13/12 were significantly 
higher in 12–13 and 14–15 age groups.
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Figure 2. 
Priming with different 1990s human seasonal influenza A(H3N2) (sH3N2) viruses in US 
children influences seroprevalence of hemagglutination-inhibition (HI) antibodies to 2012–
2013 influenza A(H3N2) variant (H3N2v) virus. Serum samples from children aged 12–18 
years (n = 118) were collected in 2010; median ages are for this year. HI geometric mean 
titers (GMTs) and seroprevalence against the 2 H3N2v and 4 sH3N2 viruses are shown for 3 
groups of children likely to have been primed with SY/97 (A, D), WH/95 (B, E), or BJ/92 
cluster (C, F). *Significantly higher seroprevalence and HI GMTs against A/Indiana/06/2013 
(IN/6/13) compared with A/Ohio/13/2012 (OH/13/12) in groups 1 and 2 (P < .01). 
Abbreviation: SD, standard deviation.
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Figure 3. 
Age distribution in 3 groups of children (aged 12–18 years, n = 118) likely to have been 
primed with SY/97, WH/95, or BJ/92 cluster. Median ages shown are for 2010.
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Table 1
Periods of Prevalence for sH3N2 Viruses Used in Current Study
Reference Strain (Abbreviation) Eras of Prevalencea Prominent Seasonsb Vaccine-Use Erasa
A/Aichi/2/1968 (AI/68) 1968–1972 1968–1969; 1969–1970; 1971–1972 1968–1969; 1969–1970; 1970–1971; 
1971–1972; 1972–1973
A/Victoria/3/1975(VIC/75) 1975–1977 1975–1976 1976–1977; 1977–1978
A/Bangkok/1/1979(BK/79) 1979–1983 1980–1981; 1982–1983 1980–1981; 1981–1982; 1982–1983;
A/Shanghai/11/1987(SH/87) 1987–1990 1987–1988; 1989–1990 1989–1990
A/Beijing/32/1992(BJ/92) 1992–1996 1992–1993; 1993–1994 1993–1994
A/Wuhan/359/1995(WH/95) 1995–1998 1996–1997 1996–1997; 1997–1998
A/Sydney/5/1997(SY/97) 1997–2000 1997–1998; 1998–1999; 1999–2000 1998–1999; 1999–2000
A/Fujian/411/2002(FJ/02) 2002–2005 2003–2004 2004–2005
A/Brisbane/10/2007(BR/07) 2007–2009 2007–2008 2008–2009; 2009–2010
Abbreviation: sH3N2, human seasonal influenza A(H3N2).
a
Data from previous publications [34, 35] and annual US influenza virus surveillance data.
b
Prominent influenza seasons were defined as those in which ≥20% of isolates typed and subtyped in that season were the sH3N2 virus [35].
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